|
|
|
| Should we invariably follow the current guidelines to treat our HCC patients? |
| Wen-Tao Yan a , b , Bing Quan a , b , Jiong-Jie Yu a , b , Tian Yang a , ∗ |
a Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China
b Department of Clinical Medicine, Second Military Medical University, Shanghai 200433, China
∗ Corresponding author.
E-mail address: yangtianehbh@smmu.edu.cn (T. Yang). |
|
|
|
|
Abstract We read with great interest the article by Dr. Vitale et al. [1] , which developed an ITA.LI.CA scoring system to improve the prognostic utility for patients with re-staging hepatocellular carcinoma (HCC) before additional therapies. We appreciate the authors’ work and believe that the study has important value in guiding reasonable treatments for HCC. Herein, we would like to raise the following comments.
|
|
|
|
|
|
|
|
|
2019, Vol. 18 
